News and Trends 24 Mar 2023Evotec receives $6.6M for tuberculosis drug discovery On World Tuberculosis Day, Evotec SE has announced that it has received a $ 6.6 million grant from The Bill… March 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2023Microbiome therapeutics biotech mbiomics raises €13M mbiomics GmbH, a German microbiome biotech company developing the first generation of effective microbiome-based therapeutics has closed €13 million ($… March 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2023Intracellular “smoke detector” discovery has skin disease therapy implications A study by the University of Bonn in Germany could lead to therapies against skin and intestinal diseases in the… March 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2023How the microbiome can predict cancer immunotherapy success A new study shows antibiotic treatment prior to CAR-T cell therapy is connected to unfavorable treatment outcomes. An international team… March 14, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Mar 2023Partnership formed to develop miRNA to treat pancreatic cancer RNA delivery and therapeutics company SiSaf Ltd is to collaborate with the University of Leipzig in Germany to develop targeted… March 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Feb 2023Crown Bioscience acquiring Indivumed’s service business and biobank Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has entered into an agreement to… February 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023Beyond Biotech podcast 28: Mainz Biomed, Newron Pharmaceuticals This week, we have two guests. We have conversations with Newron CEO, Stefan Weber, and Mainz Biomed CEO, Guido Bächler.… January 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023Researchers discover new type of CRISPR gene scissors Scientists at the Helmholtz Institute Würzburg in Germany, and Benson Hill, Inc. (Missouri) and Utah State University in the U.S.,… January 5, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2022Watch: Atriva Therapeutics at BIO-Europe Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet… December 19, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2022Watch: Adrenomed tackling huge issue of sepsis Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Its mission is to rescue vascular integrity in order to… December 19, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data OSE Immunotherapeutics SA has presented the latest preclinical data on the use of its anti-IL-7 receptor (IL-7R) antagonist OSE-127 for… December 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022INSPIRE launched to develop inhaled gene therapy for the treatment of lung cancer OmniSpirant Limited and EVerZom have launched INSPIRE, a €12.8 million ($13.4 million) lung cancer project funded by Horizon Europe. In… December 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2022Partnership to deliver oncology workflow for 7 European hospitals A BC Platforms (BCP) partnership that includes Finland’s Euformatics and Hungary’s Oncompass Medicine has been awarded a contract for the… December 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2022Creating designer immune cells at scale To prevent testing on animals and create more precise ways of testing therapeutics, the pharmaceutical industry is turning to human… December 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2022New function of CRISPR gene scissors discovered For several years, the CRISPR/Cas9 gene scissors have been causing a sensation in science and medicine. Researchers from the Institute… November 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 23 Nov 2022What recent mixed clinical results can teach about Alzheimer’s disease 2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO of the German biotech Vivoryon,… November 23, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022Concern as study says new covid sub-variant is resistant to all therapeutic antibodies All approved antibody therapies for Covid-19 are ineffective against the Omicron sub-lineage BQ.1.1. That’s the worrying news following a recent… November 23, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2022CatalYm raises €50M to boost solid tumors trial CatalYm has announced the close of a €50 million ($49 million) series C financing round. The oversubscribed round was co-led… November 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2022Beyond Biotech podcast 23: World Antimicrobial Awareness Week, PsychoGenics This week, we have three interviews on the theme of antimicrobial resistance (AMR), to mark World Antimicrobial Awareness Week. We… November 18, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022FundaMental Pharma launches with €10M to advance first-in-class neuroprotectant FundaMental Pharma GmbH, a preclinical neuroscience company spun out of Heidelberg University in Germany, has launched with €10 million ($10.4… November 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email